Figure 6. Selectin-deficient NK cells are defective in tumor target cell rejection in vivo.

A. Inset: B16F0 tumor cells were stably infected with either a construct carrying the Rae1ε NK cell-activating antigen (B16-Rae1ε cells) or with a vector control (B16-puro cells). Rae1ε antigen expression was confirmed by FACS. 1×10⁴ B16-Rae1ε or B16-puro cells were injected s.c. into mice treated with control or NK-depleting TM-β1 antibody, or into Ly49A-GrzAtg⁺ and control tg^- animals. Tumor growth was assayed by measuring tumor length (L) and width (W) with calipers every other day and multiplying the values together to obtain tumor surface area (L*W=surface area, mm²). B. 1×10⁴ B16-Rae1ε or B16-puro cells were injected s.c. into selectin-deficient mice. Boxed numbers indicate number of mice that developed a tumor out of the total number of mice assayed. Results are expressed as line graphs of mean tumor surface area of 5-18 individual mice, error bars = SEM